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patients in the Swedish MS registry for the Stockholm County.
Patients withdrawing from treatment in both arms were assumed
to follow the disease course of 824 patients with relapsing-
remitting disease at onset in the natural history cohort in
Ontario, Canada. Costs and utilities by level of disease severity
are based on a recent observational study in 1339 Swedish
patients. All data sets were available at patient-level. Main re-
sults are presented for the societal perspective, over a 20-year
time frame, in 2005 Euro (1€ = 9.25SEK) discounted at 3%.
RESULTS: In the base case, treatment with natalizumab was less
expensive and more effective than treatment with current DMDs
in Sweden, i.e. it dominated standard therapy. When only health
care costs were considered, the cost per QALY gained with
natalizumab was €38,145. Health effects are sensitive only to the
time horizon of the analysis, and assumptions about effective-
ness of natalizumab beyond the trial. CONCLUSION: This
cost-effectiveness analysis used registry data, cohort and obser-
vational studies to extrapolate the efﬁcacy ﬁndings of natali-
zumab from the AFFIRM clinical trial to measure effectiveness
in clinical practice. The analysis results suggest that for the
population considered, natalizumab provides an additional
health beneﬁt at a similar cost to current DMDs from a societal
perspective.
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OBJECTIVES: Markov modeling has been widely used to
assess the cost-effectiveness of disease modifying drugs (DMDs)
in patients with relapsing form of multiple sclerosis (RFMS). Its
limitations, along with variations in disease progression, often
lead to unrealistic clinical assumptions and oversimpliﬁcation
of the course of RFMS. This study assessed the reliability of
modeling clinical outcomes for patients receiving interferon-
beta-1a (IFNb1a) subcutaneously (SC) versus intramuscularly
(IM) using discrete event simulation (DES). METHODS: The
model creates a cohort of individual patients by reading in
actual patient proﬁles and “cloning” them-one receives IFNb1a
SC, and the other IM. Patients may suffer relapses, develop new
T2 lesions, experience adverse events, stop treatment, progress
to secondary progressive MS or die. Time for each event is
sampled from failure time distributions speciﬁed by the indi-
vidual’s risk proﬁle. When a relapse occurs, an actual relapse
proﬁle comprising severity and recovery status is assigned and
processed accordingly. Model inputs were mostly derived from
the EVidence of Interferon Dose-response European North
American Comparative Efﬁcacy (EVIDENCE) trial with a few
from published literature. Results based on 100 replications of
10,000 patient pairs were validated against the trial results.
RESULTS: Predictions at 64 weeks, the mean follow-up of the
EVIDENCE trial, were similar to the trial RESULTS: Fifty-four
percent vs. 56% (model vs. trial) of SC and 45% vs. 48% of
IM users remained relapse-free and the annual relapse rate was
0.51 vs. 0.54 with SC and 0.66 vs. 0.65 with IM use. Of
relapses, 57% required no treatment, 36% an outpatient visit,
and 7% a hospital stay, almost identical to the trial results with
57%, 36%, and 8%, respectively. CONCLUSION: Use of DES
permits realistic modeling of DMDs in RFMS, use of actual
patient-level data, and avoided unrealistic assumptions, while
closely predicting the clinical outcomes with efﬁciency, ﬂexibil-
ity and transparency.
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OBJECTIVES: To assess the cost-effectiveness of the Versatis
lidocaine 5% medicated plaster relative to 300 and 600 mg/day
pregabalin in the treatment of post-herpetic neuralgia (PHN)
from the perspective of the Scottish National Health Service.
METHODS: The costs and beneﬁts of the three treatments were
assessed over a six-month time horizon using a Markov model.
The model structure allowed for differences in costs, utilities and
transition probabilities between the initial 30-day run-in period
and maintenance therapy and took account of add-in medication
and drugs received by patients discontinuing therapy. Transition
probabilities were based on clinical trials and Delphi panel
estimates. Resource use and add-in/switch medications were
obtained from 2 Delphi panels; cost data were from ofﬁcial price
tariffs. Published utilities were adjusted for age and were
supplemented/validated by a Delphi panel. Lidocaine-treated
patients were assumed to receive 1.03 plasters/day based on US
prescribing data. RESULTS: The average patient receiving the
lidocaine plaster accrued 0.292 quality-adjusted life-years
(QALYs) over six months—0.067 more than 300 mg pregabalin
and 0.061 more than 600 mg pregabalin. The total treatment
cost for patients receiving the lidocaine plaster (£681/patient)
was very similar to that for 300 mg pregabalin (£636/patient)
and 600 mg pregabalin (£655/patient). The lidocaine plaster cost
£674/QALY (95% conﬁdence interval [95% CI]: dominant,
£4,780) relative to 300 mg/day pregabalin and £434/QALY
(95% CI: dominant, £5,009) relative to 600 mg/day pregabalin.
Probabilistic sensitivity analysis demonstrated that we can be
99.9% conﬁdent that the lidocaine plaster is cost-effective rela-
tive to 300 mg pregabalin and 99.8% conﬁdent that it is cost-
effective relative to 600 mg pregabalin at a £20,000/QALY
threshold. The lidocaine plaster cost £27 per additional month
with sufﬁcient pain relief and no intolerable side-effects relative
to 300 mg pregabalin and £18/month relative to 600 mg pre-
gabalin. CONCLUSION: The Versatis lidocaine 5% medicated
plaster is a highly cost-effective alternative to pregabalin for the
treatment of PHN in Scotland.
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OBJECTIVES: The currently available formulations budesonide/
formoterol (BUD/FORM, Symbicort) and salmeterol/ﬂuticasone
(SAL/FLU, Seretide) have been shown to be effective in the treat-
ment of asthma. This study compared outcomes with BUD/
FORM and SAL/FLU in real-life practice. METHODS: Cohorts
of asthma patients initiated on BUD/FORM or SAL/FLU
between 2001 and 2006 were identiﬁed from IMS Disease Ana-
lyzer, a longitudinal UK database of physician records. Patients
were followed 12 months before and after treatment initiation
(TI). Treatment success was deﬁned as no oral corticosteroid
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prescription (OCS) or hospitalisation, no change in maintenance
therapy and a mean daily short-acting b2-agonist (SABA) con-
sumption < 0.5 doses/day. Baseline demographics, co-morbidity
and asthma medication before TI was used to construct regres-
sion models to control for factors potentially inﬂuencing out-
comes. RESULTS: Respectively, 2701 and 7320 patients were
included in the BUD/FORM and SAL/FLU cohorts, respectively,
with no signiﬁcant difference in age, gender, co-morbidity, ICS
dose, SABA use or hospitalisations at baseline while active
smokers, asthma consultations and OCS prescriptions were
slightly lower in the BUD/FORM group. Use of SABA and
asthma consultations decreased in both cohorts following TI. In
unadjusted analysis a higher proportion of treatment success was
seen in the BUD/FORM group following TI compared to SAL/
FLU (25.3 vs. 23.0%, p < 0.05). This result was driven by fewer
patients in the BUD/FORM group with an OCS prescription and
high SABA use. In multivariate binary regression analysis, BUD/
FORM was not signiﬁcantly associated with greater odds of
success than SAL/FLU (OR, 95% CI: 1.11, 0.99–1.23). Variables
signiﬁcantly associated with success were age, female sex, no
rhinitis and low OCS and SABA use pre TI. Resource use (hos-
pitalisations and asthma consultations) was similar between
groups post TI. CONCLUSION: Initiating treatment with BUD/
FORM or SAL/FLU in real-life practice improved outcomes to a
similar magnitude, although there were trends to better outcomes
associated with BUD/FORM.
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OBJECTIVES: Patients with pneumonia and respiratory failure
usually require intensive care unit (ICU) admission. Because of
high acuity and the need for expensive interventions, concern
exists over the ability of DRG reimbursement to cover inpatient
costs. This study evaluated the costs and DRG reimbursement
associated with the care of pneumonia and concurrent respira-
tory failure. METHODS: Forty-six consecutive patients with
complete data sets enrolled in the VALID study, a phase III
multicenter study evaluating recombinant SP-C-based surfactant
treatment (Venticute®, ALTANA, Konstanz, Germany) in
patients with pneumonia and respiratory failure, in 9/2006 were
included. Total costs (ICU/non-ICU) were assessed, assumed
daily costs were $1,238 (US$) for ICU without ventilation,
$2,760 with ventilation, $1,004 for stepdown, and $770 for
ward. FY07 reimbursement was determined by multiplying the
relative weight for each DRG code by a base rate of US$6,000.
For outlier payment calculations, the threshold for FY2006 of
$23,300.00 was used. Costs above regular reimbursement plus
this threshold were reimbursed at 80%. RESULTS: Mean age
was 53.2 + 16.3 (mean + SD), with a mean APACHE II score of
17.4 + 6.4. Mean hospital LOS = 29 days, with mean ICU, step-
down, and ward LOS of 22, 2 and 5 days respectively. Mean
duration of ventilation was 17 days (range 2–49). Total costs
averaged $58,242, with 46.1% of all costs accounting for ICU
care (excluding ventilation), 44.0% for ventilation, and 103.5%
and 6.4% for stepdown and ward respectively. Across all DRGs,
the average shortfall (cost minus reimbursement) equaled
$20,897 with a loss occurring in 36/47 (76.6%) patients. CON-
CLUSION: This preliminary analysis suggests that DRGs fail to
cover costs associated with pneumonia and respiratory failure.
This potentially places hospitals that care for these patients at
signiﬁcant ﬁnancial risk and suggests the needs for revision in
reimbursement schemes to insure a more equitable payment rela-
tive to expected resource consumption.
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OBJECTIVES: It is hypothesised that socio-economic factors
play a key role in determining treatment patterns. This study
investigated the impact of employment and gender on asthma
treatment patterns in 2526 patients in the US, Germany and
Spain. METHODS: The data were drawn from the Adelphi
Disease Speciﬁc Programme (DSP) in asthma, a cross-sectional
study of consulting patients undertaken in 2007. Data were
collected by doctors who were asked to include the next 6
patients consulting for asthma from a speciﬁed start date. Key
factors analysed were gender and employment status (skilled,
unskilled, and unemployed). Chi-square and Fisher’s exact tests
were used to test for differences. RESULTS: There was a signiﬁ-
cant relationship between employment status and patients’ level
of knowledge about their condition. Skilled workers had a higher
level of knowledge as compared to unskilled workers (US: 37.3%
vs. 18.3%, p < 0.001; Germany: 35.3% vs. 22.5%, p < 0.05;
Spain: 26.7% vs. 15.9%, p = 0.06). Skilled workers also had
more involvement in treatment decisions (US: 50.0% vs. 32.3%,
p < 0.001; Germany: 35.3% vs. 18.8%, p < 0.001; Spain: 21.6%
vs. 13.4%, p = 0.1) and were rated more compliant than
unskilled workers (US: 56.3% vs. 37.1%, p < 0.001; Germany:
45.3% vs. 28.4%, p < 0.01; Spain: 35.1% vs. 23.2%, p = 0.06).
There were no signiﬁcant differences between genders other than
Spain where signiﬁcantly more men had a higher level of knowl-
edge about their condition (24.5% vs. 17.2%, p < 0.01) and
more involvement in their treatment (20.9% vs. 14.5%,
p < 0.05). In all countries a signiﬁcant positive correlation was
found between level of involvement and compliance with treat-
ment (p < 0.01). CONCLUSION: There are signiﬁcant differ-
ences in knowledge, involvement and compliance between socio-
economic groups in the US, Germany and Spain. The signiﬁcant
correlation between level of involvement and compliance may
indicate that if physicians made particular efforts with lower
socio-economic groups in treatment decisions compliance levels
would improve.
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OBJECTIVES: To compare medical costs and utilization in
patients on single controller inhaled corticosteroid (ICS) to other
asthma drug regimens. Medical costs and health care utilization
associated with asthma and the variation by treatment are poorly
understood. METHODS: Direct medical costs and utilization
were captured from administrative electronic databases from
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